Compare PLTK & CAPR Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
Current Price
| Metric | PLTK | CAPR |
|---|---|---|
| Founded | 2010 | 2005 |
| Country | Israel | United States |
| Employees | N/A | N/A |
| Industry | EDP Services | Biotechnology: Biological Products (No Diagnostic Substances) |
| Sector | Technology | Health Care |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 1.1B | 1.3B |
| IPO Year | 2020 | 2011 |
| Metric | PLTK | CAPR |
|---|---|---|
| Price | $3.14 | $31.59 |
| Analyst Decision | Buy | Strong Buy |
| Analyst Count | 6 | 8 |
| Target Price | $5.04 | ★ $44.63 |
| AVG Volume (30 Days) | ★ 1.5M | 1.3M |
| Earning Date | 05-07-2026 | 05-12-2026 |
| Dividend Yield | ★ 12.74% | N/A |
| EPS Growth | N/A | ★ N/A |
| EPS | ★ N/A | N/A |
| Revenue | ★ $2,755,400,000.00 | N/A |
| Revenue This Year | $2.60 | N/A |
| Revenue Next Year | $2.23 | N/A |
| P/E Ratio | N/A | ★ N/A |
| Revenue Growth | ★ 8.08 | N/A |
| 52 Week Low | $2.64 | $4.30 |
| 52 Week High | $5.59 | $40.37 |
| Indicator | PLTK | CAPR |
|---|---|---|
| Relative Strength Index (RSI) | 56.62 | 58.24 |
| Support Level | N/A | $25.33 |
| Resistance Level | $3.82 | $36.49 |
| Average True Range (ATR) | 0.13 | 1.91 |
| MACD | 0.05 | 0.01 |
| Stochastic Oscillator | 84.35 | 73.85 |
Playtika Holding Corp is engaged in developing mobile games. Some of its games include Board Kings, House of Fun, Poker Heat, Slotomania, and Bingo Blitz. The company has built live game operations services and a proprietary technology platform to support its portfolio of games. It derives revenue from the sale of virtual items associated with online games. Geographically, the group has a business presence in the USA, EMEA, APAC, and Other regions of which key revenue is derived from the USA. The company offers both Mobile and Web-based platforms.
Capricor Therapeutics Inc is a clinical-stage biotechnology company focused on the development of transformative cell and exosome-based therapeutics for treating Duchenne muscular dystrophy (DMD), a rare form of muscular dystrophy which results in muscle degeneration and premature death, and other diseases with high unmet medical needs. The company's product pipeline includes CAP-1002, deramiocel an allogeneic cardiac-derived cell therapy. Deramiocel is currently advancing through Phase 3 clinical development for the treatment of Duchenne muscular dystrophy. Through its proprietary StealthXTM platform, the group uses its exosome technology to conduct preclinical research focused on vaccinology, delivering oligonucleotides, proteins, and small molecules to treat.